{"product_id":"ss31-10mg","title":"SS31 10mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/ss31-10mg_627cd29c-9356-4b11-89e7-afaeea5f0afb.png?v=1779544505\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eMitochondrial support peptide designed for cellular energy optimization. SS31 is a targeted bioactive compound that crosses the blood-brain barrier to support mitochondrial function and ATP production. Each vial contains 10mg of pharmaceutical-grade peptide, ideal for research and performance-focused protocols. Store at 2–8°C. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eActive Ingredient: SS31 (Elamipretide) Quantity: 10mg per vial Purity: Pharmaceutical grade Form: Lyophilized powder Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture Solubility: Reconstitute with sterile water or saline Molecular Weight: 623.7 Da Sequence: D-Arg-2’,6’-dimethyltyrosine-Lys-Phe-NH2 Application: Research and investigational use Sterility: Tested and certified Endotoxin: \u0026lt;5 EU\/vial\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₃₄H₅₂N₁₀O₈ CAS Number: 736992-21-1 IUPAC Name: (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid Exact Mass: 720.39 g\/mol Chemical Class: Tetrapeptide analogue Structural Type: Mitochondrial-targeting peptide Composition: 4 amino acid residues with D-arginine modification Purity Grade: ≥98% (HPLC)\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Temperature: 2–8°C (refrigerated) Container: Original sealed vial Light Protection: Store in dark conditions or original packaging Humidity: Keep in dry environment Duration: Stable for 24 months from manufacture date Handling: Minimise exposure to air and moisture Storage After Reconstitution: Temperature: 2–8°C (refrigerated) Container: Sterile, sealed vial or container Stability: Use within 7 days of reconstitution Preparation: Reconstitute with sterile water or 0.9% saline solution Freeze-Thaw: Avoid repeated freeze-thaw cycles Sterility: Maintain aseptic technique during and after reconstitution Discard: Any unused reconstituted solution after 7 days\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 Design and Mitochondrial Targeting Mechanism\u003c\/strong\u003e\u003cbr\u003eSzeto HH. (2006). \u003cem\u003eCell-permeable, mitochondria-targeted, peptide antioxidants.\u003c\/em\u003e AAPS Journal, 8(2), E277–E283. \u003ca href=\"https:\/\/doi.org\/10.1007\/BF02854898\"\u003ehttps:\/\/doi.org\/10.1007\/BF02854898\u003c\/a\u003e\u003cbr\u003eFoundational paper by the inventor of the SS peptide series, describing the design rationale for SS31 (Elamipretide) as a cell-permeable, mitochondria-targeted antioxidant tetrapeptide. Establishes the cardiolipin-binding mechanism and selective accumulation in the inner mitochondrial membrane.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 and Cardiolipin Interaction: Preserving Mitochondrial Cristae\u003c\/strong\u003e\u003cbr\u003eBirk AV, et al. (2013). \u003cem\u003eThe mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.\u003c\/em\u003e Journal of the American Society of Nephrology, 24(8), 1250–1261. \u003ca href=\"https:\/\/doi.org\/10.1681\/ASN.2012121216\"\u003ehttps:\/\/doi.org\/10.1681\/ASN.2012121216\u003c\/a\u003e\u003cbr\u003eDemonstrates that SS31 binds directly to cardiolipin on the inner mitochondrial membrane, stabilising cristae architecture, restoring electron transport chain efficiency, and improving ATP synthesis in ischaemic renal tissue — a key mechanistic study for mitochondrial bioenergetics research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 in Cardiac Ischaemia-Reperfusion Injury Models\u003c\/strong\u003e\u003cbr\u003eCho J, et al. (2007). \u003cem\u003ePotent mitochondria-targeted peptides reduce myocardial infarction in rats.\u003c\/em\u003e Coronary Artery Disease, 18(3), 215–220. \u003ca href=\"https:\/\/doi.org\/10.1097\/MCA.0b013e3280d609fe\"\u003ehttps:\/\/doi.org\/10.1097\/MCA.0b013e3280d609fe\u003c\/a\u003e\u003cbr\u003eDemonstrates significant reduction in myocardial infarct size following SS31 administration in rat ischaemia-reperfusion models, establishing its cardioprotective profile and supporting research into mitochondrial ROS scavenging during oxidative injury.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 and Skeletal Muscle Mitochondrial Function in Ageing\u003c\/strong\u003e\u003cbr\u003eSiegel MP, et al. (2013). \u003cem\u003eMitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.\u003c\/em\u003e Aging Cell, 12(5), 763–771. \u003ca href=\"https:\/\/doi.org\/10.1111\/acel.12102\"\u003ehttps:\/\/doi.org\/10.1111\/acel.12102\u003c\/a\u003e\u003cbr\u003eShows that acute SS31 treatment rapidly restores mitochondrial membrane potential, increases ATP production, and improves in vivo skeletal muscle contractile function in aged mice — providing key data for research into age-related mitochondrial decline and sarcopenia models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eElamipretide (SS31) Clinical Translation: Heart Failure\u003c\/strong\u003e\u003cbr\u003eGibson CM, et al. (2016). \u003cem\u003eEMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients with ST-segment elevation myocardial infarction.\u003c\/em\u003e European Heart Journal, 37(16), 1296–1303. \u003ca href=\"https:\/\/doi.org\/10.1093\/eurheartj\/ehv597\"\u003ehttps:\/\/doi.org\/10.1093\/eurheartj\/ehv597\u003c\/a\u003e\u003cbr\u003ePhase 2a clinical trial evaluating the safety and tolerability of intravenous elamipretide (SS31\/MTP-131) in STEMI patients, providing translational context for preclinical SS31 research and establishing the compound’s clinical pharmacokinetic and safety profile.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248680132951,"sku":"2S10","price":26.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/ss31-10mg_627cd29c-9356-4b11-89e7-afaeea5f0afb.png?v=1779544505","url":"https:\/\/www.mutantpeptides.com\/products\/ss31-10mg","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}